Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
Apellis Shares Are Trading Lower After the Company Announced the CHMP Has Adopted a Negative Opinion on the Marketing Authorization Application of Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.